ALTA-808
Amyotrophic Lateral Sclerosis (ALS)
PreclinicalIND-enabling studies launching
Key Facts
Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Preclinical
Status
IND-enabling studies launching
Company
About Alteron Therapeutics
Alteron Therapeutics is a private, preclinical-stage biotechnology company focused on discovering and developing precision therapies targeting TDP-43 proteinopathy, a root cause of several neurodegenerative diseases including ALS, Alzheimer's disease, and frontotemporal lobar degeneration (FTLD), as well as cystic fibrosis. The company's core innovation is the ALTA series of small molecule drugs designed to inhibit TDP-43's toxic nucleic acid binding by targeting its guanine pocket. Founded in the late 2010s and incubated at Western Michigan University, Alteron is advancing its lead candidate, ALTA-808, towards IND-enabling studies with the goal of rapidly reversing symptoms in debilitating conditions.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT520-34 | Neuropore Therapies | Pre-clinical/Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Phase 2/3 (Platform Trial) |
| CNM-Au8 | Clene | Phase 2/3 |
| Masitinib | AB Science | Phase 3 |
| Undisclosed Program | Zhimeng Biopharma | Clinical |
| SLS-005 | Seelos Therapeutics | Platform Trial |
| PMN442 | ProMIS Neurosciences | Preclinical |
| nAV-101 | nVector | Pre-clinical |
| GM6 | Genervon Biopharmaceuticals | Phase 2 |
| Lou Gehrig’s disease | Genclis | Discovery |
| Treg-directed therapy for ALS | Iltoo Pharma | Pre-clinical |
| NG CELL | NeuroGenesis Bio | Phase 2 |